EGFR and neoplasm: In particular, BP-αCD3-αEGFR-ARC Exos, which recruit and activate cytotoxic T cells toward attacking EGFR-positive breast cancer cells as well as promote T-lymphocyte infiltration to tumors on bones, displayed enhanced therapeutic efficacy for tumor expansion and metastasis in different mouse xenograft models.